ContraVir Pharma (CTRV) Soars on CMX157 Breathtaking Potency; Alcoa (AA) Upward Session
Shares of ContraVir Pharmaceuticals, Inc. (Nasdaq:CTRV) soared to touch an all-time high on Monday’s trading session after the company said that its drug candidate CMX157 was shown to be 60 times more active against the hepatitis B virus than Gilead Sciences‘ (Nasdaq:GILD) tenofovir, based on in vitro studies.
CTRV stock is currently exchanging hands at around $4.51, up $2.40 (or +113.75%), with 20,711,185 shares traded so far, a huge increase in activity versus its average volume (3m) of 50,427
ContraVir Pharmaceuticals, a biopharmaceutical company, has 22.30M Shares Outstanding and CTRV stock 52-week range is $0.65 – $6.28 per share
Alcoa Inc. (NYSE:AA) stock surged in early trade Monday as the company reported that it has signed an approximately $1 billion contract with Airbus.
Brokerage firm Gabelli & Co. has initiated coverage on Alcoa’s stock with a Buy rating and a price target of $14.50 per share.
AA stock is currently trading for about $10.24, up $0.71 (or +7.51%), and 22,500,515 of its shares exchanged hands so far
Alcoa, an aluminum company, has 1.31B Shares Outstanding and AA stock 52-week range is between $7.97 and $17.75 per share
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/